The antibody drug conjugates market size has grown exponentially in recent years. It will grow from $8.78 billion in 2023 to $10.7 billion in 2024 at a compound annual growth rate (CAGR) of 21.9%. The growth observed during the historical period in the antibody-drug conjugates (ADCs) market can be attributed to factors such as the increasing prevalence of cancer, successful clinical outcomes leading to regulatory approvals, strategic collaborations between pharmaceutical companies, a rise in investment in research and development (R&D) initiatives, and the implementation of market expansion strategies.
The antibody drug conjugates market size is expected to see exponential growth in the next few years. It will grow to $24.8 billion in 2028 at a compound annual growth rate (CAGR) of 23.4%. The anticipated growth in the forecast period in the antibody-drug conjugates (ADCs) market can be attributed to factors such as the development of next-generation ADCs, expanding indications for their use, an increasing focus on personalized medicine in cancer treatment, rising investment in precision medicine approaches, and a growing awareness of healthcare options. Major trends expected in the forecast period include advancements in conjugation technologies, an improved understanding of tumor biology influencing ADC development, ongoing technological advancements in the field, expanding therapeutic applications for ADCs, and the continuous evolution of advanced conjugation technologies for enhanced drug delivery.
The global antibody-drug conjugates market is witnessing significant growth driven by the increasing incidence of cancer worldwide. Primary causes of most cancers, including obesity, smoking, alcohol consumption, and poor dietary habits, contribute to a rising trend. Cancer Research UK projects a substantial increase, estimating 27.5 million new cancer cases annually by 2040. This surge in cancer incidences is expected to boost the demand for antibody-drug conjugates, thereby propelling market growth.
The upward trajectory of the antibody-drug conjugates market is further fueled by a growing number of clinical trial studies. Clinical trials, essential for testing new treatments and interventions, play a crucial role in disease management. Antibody-drug conjugates, as a significant category of anti-cancer medications, are undergoing numerous clinical trials for treating blood-related cancers and solid tumors. Notably, there has been a substantial increase in registered clinical trials worldwide, with 452,604 listed on ClinicalTrials.gov, as reported by The Xtalks in May 2023. This uptrend indicates the rising prominence of clinical studies, contributing to the expansion of the antibody-drug conjugates market.
Challenges in the manufacturing process of antibody-drug conjugates act as a restraint on market growth. ADC manufacturing facilities require substantial capital investment and specialized training for operators. The complexity of ADC process development, involving additional steps not present in conventional monoclonal antibody manufacturing, poses operational difficulties. Challenges include optimizing antibody-drug conjugation reactions and subsequent drug substance purification, along with the need for aseptic environments and protection of personnel from highly toxic drug compounds.
Manufacturers of antibody-drug conjugates are subject to monitoring by regulatory bodies, such as the Food and Drug Administration (FDA) in the USA. Although there is no specific regulatory guidance for ADC development, the FDA follows existing guidelines for small drugs and monoclonal antibodies to regulate ADC. Regulatory oversight focuses on aspects such as the manufacturing of the antibody component, control strategy for antibody intermediate, drug substance, and drug product. Small molecule review groups at the FDA play a key role in evaluating payload and linker adequacy, conjugation reactions, and aspects of the control strategy.
Manufacturers are increasingly engaging in collaborations and partnerships to share technology, resources, and product knowledge. An example is the collaboration between Sanofi, a French multinational pharmaceutical company, and Seagen Inc., a US biotechnology company, announced in March 2022. This collaboration aims to develop and market up to three cancer targets for antibody-drug conjugates, leveraging Sanofi's exclusive monoclonal antibody technology and Seagen's exclusive ADC technology. Such collaborations enhance synergies, fostering the creation of candidate medications to offer new hope to cancer patients.
Major companies in the antibody-drug conjugates market are introducing innovative breakthrough conjugates such as Ujvira to offer affordable new therapies. Ujvira, launched by Zydus Cadila in May 2021, is the world's first biosimilar antibody-drug conjugate of trastuzumab emtansine. This breakthrough treatment targets breast and stomach cancer by inhibiting the human epidermal growth factor receptor protein (HER2). Administered by qualified medical professionals, Ujvira represents a significant advancement in cancer therapy.
Major companies operating in the antibody drug conjugates market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Sorrento Therapeutics Inc., Astellas Pharma Inc., Biogen Inc., Zydus Lifesciences Limited, Seagen Inc., Seagen Inc., Progenics Pharmaceuticals Inc., Synthon BV, Genentech Inc., ImmunoGen Inc., Nordic Nanovector ASA, ADC Therapeutics SA, Immunomedics Inc., Mersana Therapeutics Inc., Heidelberg Pharma AG, Celldex Therapeutics Inc., Oxford BioTherapeutics, Concortis Biotherapeutics Corp., Antikor BioPharma Ltd., Fredax, Eisai Co. Ltd., Merck KGaA, Bracco S.p.A. North America was the largest region in the antibody-drug conjugates (ADCs) market in 2023. The Middle East is expected to be the fastest-growing region in the global antibody drug conjugates market share during the forecast period. The regions covered in the antibody drug conjugates market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The main components of antibody-drug conjugates include monoclonal antibodies, linkers, drugs or toxins, and others. Monoclonal antibodies are generated by cloning a single white blood cell, and each subsequent antibody is derived from a single parent cell. Some examples of ADC products include Adcetris, Kadcyla, and others. Various technologies, such as immunogen technology, Seattle Genetics technology, immunomedics technology, among others, are involved in the development of antibody-drug conjugates. These therapies find applications in treating conditions such as blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumors, and others, and are implemented in hospitals, clinics, and other healthcare settings.
The antibody-drug conjugates (ADCs) market research report is one of a series of new reports that provides antibody-drug conjugates (ADCs) market statistics, including antibody-drug conjugates (ADCs) industry global market size, regional shares, competitors with an antibody-drug conjugates (ADCs) market share, detailed antibody-drug conjugates (ADCs) market segments, market trends and opportunities, and any further data you may need to thrive in the antibody-drug conjugates (ADCs) industry. This antibody-drug conjugates (ADCs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The countries covered in the antibody drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The antibody-drug conjugates (ADCs) market consists of sales of enfortumab vedotin, sacituzumab govitecan, trastuzumab emtansine, and trastuzumab deruxtecan. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The antibody drug conjugates market size is expected to see exponential growth in the next few years. It will grow to $24.8 billion in 2028 at a compound annual growth rate (CAGR) of 23.4%. The anticipated growth in the forecast period in the antibody-drug conjugates (ADCs) market can be attributed to factors such as the development of next-generation ADCs, expanding indications for their use, an increasing focus on personalized medicine in cancer treatment, rising investment in precision medicine approaches, and a growing awareness of healthcare options. Major trends expected in the forecast period include advancements in conjugation technologies, an improved understanding of tumor biology influencing ADC development, ongoing technological advancements in the field, expanding therapeutic applications for ADCs, and the continuous evolution of advanced conjugation technologies for enhanced drug delivery.
The global antibody-drug conjugates market is witnessing significant growth driven by the increasing incidence of cancer worldwide. Primary causes of most cancers, including obesity, smoking, alcohol consumption, and poor dietary habits, contribute to a rising trend. Cancer Research UK projects a substantial increase, estimating 27.5 million new cancer cases annually by 2040. This surge in cancer incidences is expected to boost the demand for antibody-drug conjugates, thereby propelling market growth.
The upward trajectory of the antibody-drug conjugates market is further fueled by a growing number of clinical trial studies. Clinical trials, essential for testing new treatments and interventions, play a crucial role in disease management. Antibody-drug conjugates, as a significant category of anti-cancer medications, are undergoing numerous clinical trials for treating blood-related cancers and solid tumors. Notably, there has been a substantial increase in registered clinical trials worldwide, with 452,604 listed on ClinicalTrials.gov, as reported by The Xtalks in May 2023. This uptrend indicates the rising prominence of clinical studies, contributing to the expansion of the antibody-drug conjugates market.
Challenges in the manufacturing process of antibody-drug conjugates act as a restraint on market growth. ADC manufacturing facilities require substantial capital investment and specialized training for operators. The complexity of ADC process development, involving additional steps not present in conventional monoclonal antibody manufacturing, poses operational difficulties. Challenges include optimizing antibody-drug conjugation reactions and subsequent drug substance purification, along with the need for aseptic environments and protection of personnel from highly toxic drug compounds.
Manufacturers of antibody-drug conjugates are subject to monitoring by regulatory bodies, such as the Food and Drug Administration (FDA) in the USA. Although there is no specific regulatory guidance for ADC development, the FDA follows existing guidelines for small drugs and monoclonal antibodies to regulate ADC. Regulatory oversight focuses on aspects such as the manufacturing of the antibody component, control strategy for antibody intermediate, drug substance, and drug product. Small molecule review groups at the FDA play a key role in evaluating payload and linker adequacy, conjugation reactions, and aspects of the control strategy.
Manufacturers are increasingly engaging in collaborations and partnerships to share technology, resources, and product knowledge. An example is the collaboration between Sanofi, a French multinational pharmaceutical company, and Seagen Inc., a US biotechnology company, announced in March 2022. This collaboration aims to develop and market up to three cancer targets for antibody-drug conjugates, leveraging Sanofi's exclusive monoclonal antibody technology and Seagen's exclusive ADC technology. Such collaborations enhance synergies, fostering the creation of candidate medications to offer new hope to cancer patients.
Major companies in the antibody-drug conjugates market are introducing innovative breakthrough conjugates such as Ujvira to offer affordable new therapies. Ujvira, launched by Zydus Cadila in May 2021, is the world's first biosimilar antibody-drug conjugate of trastuzumab emtansine. This breakthrough treatment targets breast and stomach cancer by inhibiting the human epidermal growth factor receptor protein (HER2). Administered by qualified medical professionals, Ujvira represents a significant advancement in cancer therapy.
Major companies operating in the antibody drug conjugates market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Sorrento Therapeutics Inc., Astellas Pharma Inc., Biogen Inc., Zydus Lifesciences Limited, Seagen Inc., Seagen Inc., Progenics Pharmaceuticals Inc., Synthon BV, Genentech Inc., ImmunoGen Inc., Nordic Nanovector ASA, ADC Therapeutics SA, Immunomedics Inc., Mersana Therapeutics Inc., Heidelberg Pharma AG, Celldex Therapeutics Inc., Oxford BioTherapeutics, Concortis Biotherapeutics Corp., Antikor BioPharma Ltd., Fredax, Eisai Co. Ltd., Merck KGaA, Bracco S.p.A. North America was the largest region in the antibody-drug conjugates (ADCs) market in 2023. The Middle East is expected to be the fastest-growing region in the global antibody drug conjugates market share during the forecast period. The regions covered in the antibody drug conjugates market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The main components of antibody-drug conjugates include monoclonal antibodies, linkers, drugs or toxins, and others. Monoclonal antibodies are generated by cloning a single white blood cell, and each subsequent antibody is derived from a single parent cell. Some examples of ADC products include Adcetris, Kadcyla, and others. Various technologies, such as immunogen technology, Seattle Genetics technology, immunomedics technology, among others, are involved in the development of antibody-drug conjugates. These therapies find applications in treating conditions such as blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumors, and others, and are implemented in hospitals, clinics, and other healthcare settings.
The antibody-drug conjugates (ADCs) market research report is one of a series of new reports that provides antibody-drug conjugates (ADCs) market statistics, including antibody-drug conjugates (ADCs) industry global market size, regional shares, competitors with an antibody-drug conjugates (ADCs) market share, detailed antibody-drug conjugates (ADCs) market segments, market trends and opportunities, and any further data you may need to thrive in the antibody-drug conjugates (ADCs) industry. This antibody-drug conjugates (ADCs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The countries covered in the antibody drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The antibody-drug conjugates (ADCs) market consists of sales of enfortumab vedotin, sacituzumab govitecan, trastuzumab emtansine, and trastuzumab deruxtecan. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Antibody Drug Conjugates Market Characteristics3. Antibody Drug Conjugates Market Trends and Strategies32. Global Antibody Drug Conjugates Market Competitive Benchmarking33. Global Antibody Drug Conjugates Market Competitive Dashboard34. Key Mergers and Acquisitions in the Antibody Drug Conjugates Market
4. Antibody Drug Conjugates Market - Macro Economic Scenario
5. Global Antibody Drug Conjugates Market Size and Growth
6. Antibody Drug Conjugates Market Segmentation
7. Antibody Drug Conjugates Market Regional and Country Analysis
8. Asia-Pacific Antibody Drug Conjugates Market
9. China Antibody Drug Conjugates Market
10. India Antibody Drug Conjugates Market
11. Japan Antibody Drug Conjugates Market
12. Australia Antibody Drug Conjugates Market
13. Indonesia Antibody Drug Conjugates Market
14. South Korea Antibody Drug Conjugates Market
15. Western Europe Antibody Drug Conjugates Market
16. UK Antibody Drug Conjugates Market
17. Germany Antibody Drug Conjugates Market
18. France Antibody Drug Conjugates Market
19. Italy Antibody Drug Conjugates Market
20. Spain Antibody Drug Conjugates Market
21. Eastern Europe Antibody Drug Conjugates Market
22. Russia Antibody Drug Conjugates Market
23. North America Antibody Drug Conjugates Market
24. USA Antibody Drug Conjugates Market
25. Canada Antibody Drug Conjugates Market
26. South America Antibody Drug Conjugates Market
27. Brazil Antibody Drug Conjugates Market
28. Middle East Antibody Drug Conjugates Market
29. Africa Antibody Drug Conjugates Market
30. Antibody Drug Conjugates Market Competitive Landscape and Company Profiles
31. Antibody Drug Conjugates Market Other Major and Innovative Companies
35. Antibody Drug Conjugates Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Antibody Drug Conjugates Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on antibody drug conjugates market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for antibody drug conjugates? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Type: Monoclonal Antibodies; Linker; Drug/Toxin; Other Types
2) By Product: Adcertis; Kadcyla; Other Products
3) By Technology: Immunogen Technology; Seattle Genetics Technology; Immunomedics Technology; Other Technology
4) By Application: Blood Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Brain Tumor; Other Applications
5) By End-user: Hospital; Clinics; Other End-users
Key Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Bayer AG; AstraZeneca plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- AbbVie Inc.
- Bayer AG
- AstraZeneca plc
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Millennium Pharmaceuticals Inc.
- Gilead Sciences Inc.
- Regeneron Pharmaceuticals Inc.
- Daiichi Sankyo Company Limited
- Sorrento Therapeutics Inc.
- Astellas Pharma Inc.
- Biogen Inc.
- Zydus Lifesciences Limited
- Seagen Inc.
- Seagen Inc.
- Progenics Pharmaceuticals Inc.
- Synthon BV
- Genentech Inc.
- ImmunoGen Inc.
- Nordic Nanovector ASA
- ADC Therapeutics SA
- Immunomedics Inc.
- Mersana Therapeutics Inc.
- Heidelberg Pharma AG
- Celldex Therapeutics Inc.
- Oxford BioTherapeutics
- Concortis Biotherapeutics Corp.
- Antikor BioPharma Ltd.
- Fredax
- Eisai Co. Ltd.
- Merck KGaA
- Bracco S.p.A.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 10.7 Billion |
| Forecasted Market Value ( USD | $ 24.8 Billion |
| Compound Annual Growth Rate | 23.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 34 |
